Work with academic experts in oncology

Nutrition and Cancer / Sep 14, 2020

Layosa, M. A. A., Lage, N. N., Chew, B. P., Atienza, L., Mertens-Talcott, S., Talcott, S., & Noratto, G. D. (2020). Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation. Nutrition and Cancer, 73(10), 1985–1997. https://doi.org/10.1080/01635581.2020.1817514

Nutrition and Cancer / Oct 20, 2014

Dias, M. M. dos S., Noratto, G., Martino, H. S. D., Arbizu, S., Peluzio, M. do C. G., Talcott, S., Ramos, A. M., & Mertens-Talcott, S. U. (2014). Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells. Nutrition and Cancer, 66(8), 1394–1405. https://doi.org/10.1080/01635581.2014.956252

Cancer Research / Dec 05, 2022

Mandell, J. D., Cannataro, V. L., & Townsend, J. P. (2022). Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR. Cancer Research, 83(4), 500–505. https://doi.org/10.1158/0008-5472.can-22-1508

JTO Clinical and Research Reports / Dec 01, 2022

Moore, M., Zhuo, Y., Mandell, J. D., Gaffney, S. G., & Townsend, J. P. (2022). In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report.” JTO Clinical and Research Reports, 3(12), 100418. https://doi.org/10.1016/j.jtocrr.2022.100418

Leukemia / Nov 11, 2022

Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5

JNCI: Journal of the National Cancer Institute / Apr 13, 2022

Qing, T., Mohsen, H., Cannataro, V. L., Marczyk, M., Rozenblit, M., Foldi, J., Murray, M., Townsend, J. P., Kluger, Y., Gerstein, M., & Pusztai, L. (2022). Cancer Relevance of Human Genes. JNCI: Journal of the National Cancer Institute, 114(7), 988–995. https://doi.org/10.1093/jnci/djac068

The Lancet Regional Health - Europe / Mar 01, 2022

Wells, C. R., Pandey, A., Fitzpatrick, M. C., Crystal, W. S., Singer, B. H., Moghadas, S. M., Galvani, A. P., & Townsend, J. P. (2022). Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. The Lancet Regional Health - Europe, 14, 100304. https://doi.org/10.1016/j.lanepe.2021.100304

Cancer Letters / Feb 01, 2022

Fisk, J. N., Mahal, A. R., Dornburg, A., Gaffney, S. G., Aneja, S., Contessa, J. N., Rimm, D., Yu, J. B., & Townsend, J. P. (2022). Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 526, 346–351. https://doi.org/10.1016/j.canlet.2021.11.011

Neuro-Oncology / May 04, 2021

Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021). Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology, 24(1), 29–36. https://doi.org/10.1093/neuonc/noab103

Lung Cancer / Apr 01, 2022

Tan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2022). Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden. Lung Cancer, 166, 265–269. https://doi.org/10.1016/j.lungcan.2021.10.008

Bladder Cancer / Jun 11, 2020

Yang, A., Cross, C. N., & Townsend, J. P. (2020). Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 6(2), 211–213. https://doi.org/10.3233/blc-200278

Oral Oncology / Feb 01, 2020

Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. (2020). Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology, 101, 104554. https://doi.org/10.1016/j.oraloncology.2019.104554

Oncotarget / Jul 16, 2019

Gaffney, S. G., Perry, E. B., Chen, P.-M., Greenstein, A., Kaech, S. M., & Townsend, J. P. (2019). The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget, 10(44), 4532–4545. https://doi.org/10.18632/oncotarget.27027

Clinical Cancer Research / Jun 01, 2019

Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., Townsend, J. P., Serebriiskii, I. G., Golemis, E. A., Issaeva, N., Yarbrough, W. G., Koo, J. S., & Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 25(11), 3430–3442. https://doi.org/10.1158/1078-0432.ccr-18-0440

BMC Cancer / Jan 18, 2018

Gomez, K., Miura, S., Huuki, L. A., Spell, B. S., Townsend, J. P., & Kumar, S. (2018). Somatic evolutionary timings of driver mutations. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3977-y

JNCI: Journal of the National Cancer Institute / Oct 26, 2018

Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018). Effect Sizes of Somatic Mutations in Cancer. JNCI: Journal of the National Cancer Institute, 110(11), 1171–1177. https://doi.org/10.1093/jnci/djy168

Oncotarget / Apr 27, 2018

Wilkins, J. F., Cannataro, V. L., Shuch, B., & Townsend, J. P. (2018). Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget, 9(32), 22243–22253. https://doi.org/10.18632/oncotarget.25155

Frontiers in Oncology / Apr 04, 2018

Chen, W. S., Bindra, R. S., Mo, A., Hayman, T., Husain, Z., Contessa, J. N., Gaffney, S. G., Townsend, J. P., & Yu, J. B. (2018). CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00095

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer / Apr 01, 2017

Somarelli, J. A., Ware, K. E., Kostadinov, R., Robinson, J. M., Amri, H., Abu-Asab, M., Fourie, N., Diogo, R., Swofford, D., & Townsend, J. P. (2017). PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1867(2), 101–108. https://doi.org/10.1016/j.bbcan.2016.10.006

Annals of Oncology / Jan 01, 2017

Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437

Annals of Oncology / Jan 01, 2017

Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436

Cancer Research / Sep 30, 2015

Hong, W. S., Shpak, M., & Townsend, J. P. (2015). Inferring the Origin of Metastases from Cancer Phylogenies. Cancer Research, 75(19), 4021–4025. https://doi.org/10.1158/0008-5472.can-15-1889

International Journal of Radiation Oncology*Biology*Physics / May 01, 2017

Chen, W. S., Townsend, J. P., & Yu, J. B. (2017). Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology*Biology*Physics, 98(1), 8–10. https://doi.org/10.1016/j.ijrobp.2017.01.023

Oncotarget / Aug 19, 2016

Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L., Chung, C.-Y., Ariztia, E. V., Zelent, A., Farias, E. F., & Waxman, S. (2016). Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget, 8(51), 88421–88436. https://doi.org/10.18632/oncotarget.11381

Oncotarget / Jun 07, 2016

Bansal, N., Bosch, A., Leibovitch, B., Pereira, L., Cubedo, E., Yu, J., Pierzchalski, K., Jones, J. W., Fishel, M., Kane, M., Zelent, A., Waxman, S., & Farias, E. (2016). Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 7(28), 43689–43702. https://doi.org/10.18632/oncotarget.9905

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Oncotarget / Oct 09, 2015

Bansal, N., Petrie, K., Christova, R., Chung, C.-Y., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E., Wexler, J., Ariztia, E. V., Sharma, R., Zhu, J., Bernstein, E., Zhou, M.-M., Zelent, A., Farias, E., & Waxman, S. (2015). Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget, 6(33), 34087–34105. https://doi.org/10.18632/oncotarget.6048

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

Seminars in Oncology / Feb 01, 2016

Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013

Cancer Research / Jul 15, 2016

Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591

Cancer Research / Aug 01, 2015

Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

Neuro-Oncology / Jun 01, 2022

Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452

Molecular Cancer Research / Jun 01, 2011

Markell, L. M., Masiuk, K. E., Blazanin, N., & Glick, A. B. (2011). Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS. Molecular Cancer Research, 9(6), 746–756. https://doi.org/10.1158/1541-7786.mcr-11-0112

Journal of Global Oncology / Oct 01, 2018

Callanan, M., Zawicki, V., Hinson, L., Lee, M., Triantis, S., Manbachi, A., & Harvey, S. (2018). Reusable Core Needle Biopsy Device for Low-Resource Settings. Journal of Global Oncology, 4(Supplement 3), 47s–47s. https://doi.org/10.1200/jgo.18.10550

Frontiers in Oncology / Feb 16, 2023

Thombre, R., Mess, G., Kempski Leadingham, K. M., Kapoor, S., Hersh, A., Acord, M., Kaovasia, T., Theodore, N., Tyler, B., & Manbachi, A. (2023). Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1072780

Cancers / Oct 08, 2022

Hersh, A. M., Bhimreddy, M., Weber-Levine, C., Jiang, K., Alomari, S., Theodore, N., Manbachi, A., & Tyler, B. M. (2022). Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. Cancers, 14(19), 4920. https://doi.org/10.3390/cancers14194920

Immunotherapy / Jul 01, 2020

Rossi, S., Toschi, L., Finocchiaro, G., & Santoro, A. (2020). Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy, 12(10), 715–724. https://doi.org/10.2217/imt-2019-0154

Current Problems in Cancer / Nov 01, 2018

Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001

Annals of Oncology / Mar 01, 2017

Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627

Cancer Medicine / Dec 29, 2015

Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592

Immunotherapy / Dec 01, 2016

Simonelli, M., Di Tommaso, L., Baretti, M., & Santoro, A. (2016). Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy, 8(12), 1363–1369. https://doi.org/10.2217/imt-2016-0057

JCO Precision Oncology / Jun 01, 2022

Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510

Annals of Pancreatic Cancer / Oct 01, 2019

Baretti, M., Ahuja, N., & Azad, N. S. (2019). Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals of Pancreatic Cancer, 2, 18–18. https://doi.org/10.21037/apc.2019.10.01

Journal of Clinical Oncology / May 20, 2018

Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151

Cancer Control / Jan 01, 2021

Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945

OncoImmunology / Jan 01, 2021

Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., Leatherman, J. M., Suri, R., Lopez-Vidal, T. Y., Huff, A. L., Lyman, M. R., Guinn, S. R., Baretti, M., Kagohara, L. T., Ho, W. J., Azad, N. S., Burns, W. R., He, J., Wolfgang, C. L., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.2001159

Cancer Cell / Mar 01, 2022

Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017

The Cancer Journal / Jul 01, 2019

Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390

Annals of Oncology / Oct 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84

Annals of Oncology / Sep 01, 2014

Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48

Annals of Oncology / Sep 01, 2012

Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0

Annals of Oncology / Sep 01, 2012

Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398

Cancers / Oct 30, 2022

Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347

Annals of Oncology / Sep 01, 2021

Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797

Annals of Oncology / Sep 01, 2017

Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052

Annals of Oncology / Oct 01, 2015

Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59

Cancer Research / Apr 04, 2023

Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679

Oncotarget / Jul 28, 2022

Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A., & Azad, N. S. (2022). Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. Oncotarget, 13(1), 907–917. https://doi.org/10.18632/oncotarget.28255

Annals of Oncology / Oct 01, 2019

De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Journal of Thoracic Oncology / Jan 01, 2017

Mountzios, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., Toschi, L., & Metro, G. (2017). P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 12(1), S706–S707. https://doi.org/10.1016/j.jtho.2016.11.930

Annals of Oncology / Oct 01, 2016

Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104

Annals of Oncology / Sep 01, 2016

Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29

Annals of Oncology / Sep 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29

Annals of Oncology / Sep 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03

Annals of Oncology / Jun 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167

Annals of Oncology / Jun 01, 2016

Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13

Annals of Oncology / Sep 01, 2012

Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Journal of Clinical Oncology / May 20, 2010

Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605

Clinical Colorectal Cancer / Sep 01, 2018

Baretti, M., Rimassa, L., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., & Santoro, A. (2018). Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 17(3), e489–e498. https://doi.org/10.1016/j.clcc.2018.03.010

Cancer Biology &amp; Therapy / Apr 13, 2018

Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology &amp; Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117

Gastric Cancer / Aug 16, 2016

Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1

Lung Cancer / May 01, 2016

Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006

United European Gastroenterology Journal / Jun 20, 2017

Tavakoli, N., Mokhtare, M., Agah, S., Azizi, A., Masoodi, M., Amiri, H., Sheikhvatan, M., Syedsalehi, B., Behnam, B., Arabahmadi, M., & Mehrazi, M. (2017). Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial. United European Gastroenterology Journal, 6(1), 46–54. https://doi.org/10.1177/2050640617714940

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634